Medicine Overview
Adult Dose
| Clinical Information | Administration Information |
|---|---|
|
Indication: Solid tumours Age: Adult |
Dose: Intravenous – 10-20 mg/m2 Frequency: Initial dose; may repeat every 6-8 weeks Note: Repeat depends on blood count. Do not repeat if leucocyte and platelet counts are below acceptable levels. Do not re-administer if the nadir of the leucocyte count is less than 2,000 cells/mm3. |
|
Indication: Superficial bladder tumours Age: Adult |
Dose: Intravesical – 10-40 mg Frequency: 1-3 times weekly Duration: for a total of 20 doses |
Child Dose
| Clinical Information | Administration Information |
|---|---|
|
Age: Child |
Dose: Safety and efficacy not established Note: Safety and efficacy not established |
Renal Dose
| Clinical Information | Administration Information |
|---|---|
|
Condition: Renal impairment with Serum creatinine greater than 1.7 mg/dL Condition: Renal impairment with Creatinine Clearance less than 10 mL/min Column D: Dose: Decrease dose by 25% |
Dose: Avoid use Column E: Note: Avoid use |
|
Condition: Continuous Ambulatory Peritoneal Dialysis (CAPD) |
Dose: Decrease dose by 25% Column E: Note: Decrease dose by 25% Note: Decrease dose by 25% |
Administration
- For IV use only
- Must be given through central line
Side Effect
- Hemolytic uremic syndrome (Less than 15%)
- Myelosuppression (64%)
- Nausea/vomiting (14%)
- Fever (14%)
- Stomatitis (4%)
- Increased serum creatinineeatinine (2%)
- Mucous membrane toxicity (4%)
- Fatigue
- Pulmonary toxicity
- Dyspnea
- Cystitis
- Interstitial fibrosis
- Nephrotoxicity
- Amenorrhea
- Alopecia
- Myelosuppression
- haemolytic-uraemic syndrome
Drug Interaction
Drug Interaction
| Drug Name | Risk Factors |
|---|---|
|
Tamoxifen
|
Potentially Fatal: Increased risk of haemolytic uraemic syndrome
|
|
Doxorubicin
|
Increased incidence of cardiotoxicity
|
Disease Interaction
Disease Interaction
| Disease Name | Risk Factors |
|---|---|
|
Thrombocytopenia
|
Risk of severe bleeding
|
|
Coagulation Disorders
|
Risk of uncontrolled bleeding
|
Pregnancy
Pregnancy
Lactation
Special Use
Precaution
Overdose
Pharmacology
Storage
Details coming soon
Data Sources
Clinical & regulatory information on this page is compiled from the following government sources:
DISCLAIMER: This drug information content is provided for informational purposes only and is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Patients should always consult their physician with any questions regarding a medical condition and to obtain medical advice and treatment.